secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-11-19T23:59:59+00:00
Accession:  0001171843-25-007415
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose to be acquired by Hanmi Pharmaceutical at C$2.41/share, 28% premium to 30-day VWAP
--------------------------------------------------------------------------------

- Hanmi already owns 19.93% and provided >US$30M in debt facilities over 18 months.
- Transaction requires approval of 2/3 of votes, plus minority approval; special meeting by Jan 16, 2026.
- Formal valuation by Locust Walk: fair market value range of C$1.00 to C$5.23 per share.
- Aptose will be delisted from TSX and cease Canadian reporting obligations after closing.
- Officers and directors have entered voting support agreements in favor of the arrangement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325007415/0001171843-25-007415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325007415/f8k_111925.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-007415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer